Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 2/20 | 0.59 |
| ▸ | EIF2AK2 | P19525 | 8/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.41 |
| ▸ | KDR | P35968 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2946636 | 0.87 | S1PR1 (0.79) | S1PR1HDAC1 | |
| SCHEMBL2948378 | 0.87 | S1PR1 (0.76) | S1PR1EIF2AK2PDGFRBKDRHDAC1 | |
| SCHEMBL2948958 | 0.81 | KDM4E (0.46) | S1PR1EIF2AK2KDM4ENOTUMMEN1 | |
| SCHEMBL2946511 | 0.78 | S1PR1 (0.76) | S1PR1HDAC1 | |
| SCHEMBL2946203 | 0.77 | S1PR1 (0.72) | S1PR1KDM4EHDAC1 | |
| SCHEMBL2947486 | 0.76 | S1PR1 (0.77) | S1PR1HDAC1 | |
| SCHEMBL2941597 | 0.75 | S1PR1 (0.56) | S1PR1 | |
| SCHEMBL2237377 | 0.74 | S1PR1 (1.00) | S1PR1HDAC1 | |
| SCHEMBL2950819 | 0.74 | S1PR1 (0.70) | S1PR1HDAC1 | |
| SCHEMBL2949725 | 0.73 | S1PR1 (0.69) | S1PR1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750021-B2 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2010-07-06 | — | — | US | disclosed |
| US-20090131400-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2009-05-21 | — | — | US | disclosed |
| US-7417065-B2 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2008-08-26 | — | — | US | disclosed |
| EP-1628967-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2006-03-01 | — | — | EP | disclosed |
| US-20050014725-A1 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2005-01-20 | — | — | US | disclosed |
| WO-2005000833-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM, LLC (BM) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014725-A1 | Immunosuppressant compounds and compositions | ICOS, EDNRA, NFATC1 | S1PR1 133/4885EIF2AK2 422/4885PDGFRB 1382/4885 |
| US-20090131400-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | ICOS, EDNRA, NFATC1 | S1PR1 133/4885EIF2AK2 422/4885PDGFRB 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.